PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Internal Medicine II, Feldkirch Academic Teaching Hospital, Feldkirch, Austria.\', \'Private University of the Principality of Liechtenstein, Triesen, Principality of Liechtenstein.\', \'Department of Internal Medicine I, Feldkirch Academic Teaching Hospital, Feldkirch, Austria.\', \'Department of Medical Statistics, Informatics and Health Economics, Innsbruck Medical University, Innsbruck, Austria.\', \'Medical Central Laboratories, Feldkirch, Austria.\', \'University of Zurich, Zurich, Switzerland.\', \'Onkozentrum Zürich, Swiss Tumor Immunology Institute, Zurich, Switzerland.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1111/bjh.17743
?:hasPublicationType
?:journal
  • British journal of haematology
is ?:pmid of
?:pmid
?:pmid
  • 34346068
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.036
?:rankingScore_hIndex
  • 169
is ?:relation_isRelatedTo_publication of
?:title
  • Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all